Metastatic melanoma
Information
- Disease name
- Metastatic melanoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03708328 | Active, not recruiting | Phase 1 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | October 15, 2018 | August 21, 2024 |
| NCT05155254 | Active, not recruiting | Phase 3 | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | May 17, 2022 | September 2027 |
| NCT01590069 | Active, not recruiting | Phase 1 | Aerosolized Aldesleukin in Treating Patients With Lung Metastases | June 28, 2012 | April 30, 2026 |
| NCT04967196 | Active, not recruiting | Phase 1 | Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma | September 16, 2021 | July 2025 |
| NCT05393713 | Active, not recruiting | Phase 1 | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study | June 14, 2022 | January 2026 |
| NCT01644591 | Active, not recruiting | Phase 2 | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases | August 2, 2012 | August 31, 2025 |
| NCT01659151 | Active, not recruiting | Phase 2 | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | August 3, 2012 | December 2024 |
| NCT02581930 | Active, not recruiting | Phase 2 | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | August 17, 2016 | March 5, 2025 |
| NCT02650986 | Active, not recruiting | Phase 1/Phase 2 | Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | July 14, 2017 | July 14, 2032 |
| NCT03475134 | Active, not recruiting | Phase 1 | TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) | February 21, 2018 | June 30, 2026 |
| NCT01701674 | Active, not recruiting | N/A | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | October 9, 2012 | December 15, 2025 |
| NCT03430297 | Active, not recruiting | Phase 3 | A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma | February 2, 2018 | June 30, 2024 |
| NCT01134614 | Active, not recruiting | Phase 2 | Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery | December 28, 2010 | March 8, 2025 |
| NCT04940299 | Active, not recruiting | Phase 2 | Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma | September 23, 2021 | December 31, 2024 |
| NCT05640193 | Active, not recruiting | Phase 1 | A Study of LN-144 in People With Metastatic Melanoma to the Brain | November 25, 2022 | November 2025 |
| NCT02298959 | Active, not recruiting | Phase 1 | Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | April 8, 2015 | December 31, 2024 |
| NCT05704933 | Active, not recruiting | Early Phase 1 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | June 6, 2023 | January 2027 |
| NCT05695898 | Active, not recruiting | Phase 1 | XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy | February 28, 2023 | December 31, 2025 |
| NCT03276832 | Active, not recruiting | Early Phase 1 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | December 20, 2017 | June 2024 |
| NCT02816021 | Active, not recruiting | Phase 2 | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | February 14, 2017 | February 28, 2026 |
| NCT04695977 | Active, not recruiting | Phase 2/Phase 3 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | February 24, 2021 | July 19, 2024 |
| NCT00986661 | Active, not recruiting | Phase 1 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | October 2009 | February 2023 |
| NCT04514484 | Active, not recruiting | Phase 1 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | November 22, 2021 | November 2, 2025 |
| NCT01902173 | Active, not recruiting | Phase 1/Phase 2 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | July 19, 2013 | October 6, 2024 |
| NCT04217473 | Active, not recruiting | Phase 1 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma | February 26, 2020 | December 2024 |
| NCT03175432 | Active, not recruiting | Phase 2 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | June 15, 2017 | June 30, 2026 |
| NCT02278887 | Active, not recruiting | Phase 3 | Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma | September 23, 2014 | June 2027 |
| NCT01319565 | Active, not recruiting | Phase 2 | Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI... | March 24, 2011 | June 1, 2026 |
| NCT02595866 | Active, not recruiting | Phase 1 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | April 4, 2016 | October 11, 2024 |
| NCT03149029 | Active, not recruiting | Phase 2 | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | November 27, 2017 | December 31, 2024 |
| NCT01955460 | Active, not recruiting | Phase 1 | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | October 15, 2014 | June 1, 2025 |
| NCT01989585 | Active, not recruiting | Phase 1/Phase 2 | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | March 24, 2014 | December 31, 2024 |
| NCT03898908 | Active, not recruiting | Phase 2 | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain | July 18, 2019 | October 10, 2023 |
| NCT03131908 | Active, not recruiting | Phase 1/Phase 2 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | July 17, 2017 | December 31, 2025 |
| NCT01364051 | Active, not recruiting | Phase 1 | Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies | May 25, 2011 | March 7, 2025 |
| NCT01005745 | Active, not recruiting | N/A | Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma | October 20, 2009 | December 2024 |
| NCT03873818 | Active, not recruiting | Phase 2 | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | February 21, 2019 | August 31, 2024 |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT03122522 | Active, not recruiting | Phase 2 | A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | April 17, 2017 | April 2025 |
| NCT03025256 | Active, not recruiting | Phase 1 | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease | May 2, 2018 | December 30, 2025 |
| NCT03021460 | Active, not recruiting | Phase 1 | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | January 31, 2017 | December 31, 2024 |
| NCT01416831 | Active, not recruiting | Phase 2 | Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. | July 1, 2011 | June 2024 |
| NCT02910700 | Active, not recruiting | Phase 2 | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | December 9, 2016 | December 8, 2024 |
| NCT03865212 | Active, not recruiting | Phase 1 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | June 12, 2019 | January 20, 2027 |
| NCT05470283 | Active, not recruiting | Phase 1 | Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma | September 7, 2022 | April 1, 2027 |
| NCT03864042 | Active, not recruiting | Phase 1 | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | January 2, 2018 | June 30, 2023 |
| NCT00553618 | Active, not recruiting | Phase 2 | Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients | August 2007 | August 2026 |
| NCT02360579 | Active, not recruiting | Phase 2 | Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma | September 2015 | January 15, 2025 |
| NCT03816332 | Active, not recruiting | Phase 1 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers | November 8, 2019 | September 22, 2024 |
| NCT05169957 | Active, not recruiting | Phase 1 | Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) | August 9, 2022 | June 13, 2025 |
| NCT02224781 | Active, not recruiting | Phase 3 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | September 8, 2015 | December 31, 2024 |
| NCT01119508 | Completed | Phase 2 | Ipilimumab + Temozolomide in Metastatic Melanoma | May 2010 | August 2016 |
| NCT01134250 | Completed | Phase 1/Phase 2 | Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients | August 6, 2008 | April 7, 2014 |
| NCT04789668 | Completed | Phase 1/Phase 2 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | January 15, 2021 | December 8, 2023 |
| NCT04752267 | Completed | Early Phase 1 | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases | February 15, 2021 | September 18, 2023 |
| NCT04698187 | Completed | Phase 2 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | March 11, 2021 | February 5, 2024 |
| NCT01216696 | Completed | Phase 2 | Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 | November 2010 | August 2016 |
| NCT04698161 | Completed | Establishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic Diseases | February 25, 2021 | July 11, 2022 | |
| NCT01258855 | Completed | Phase 2 | Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | January 18, 2011 | March 29, 2018 |
| NCT01335009 | Completed | Phase 2 | Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma | May 16, 2011 | April 10, 2020 |
| NCT03875079 | Completed | Phase 1 | A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma | June 24, 2019 | July 14, 2022 |
| NCT01415167 | Completed | PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy | August 2011 | May 2018 | |
| NCT01425008 | Completed | Phase 1 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | September 15, 2011 | October 16, 2018 |
| NCT03850691 | Completed | Phase 2 | Radiation and Combination Immunotherapy for Melanoma | May 28, 2019 | December 12, 2022 |
| NCT03817125 | Completed | Phase 1 | Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | January 28, 2019 | March 4, 2022 |
| NCT01497808 | Completed | Phase 1/Phase 2 | RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA | November 29, 2011 | October 12, 2015 |
| NCT01558349 | Completed | Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques | June 27, 2013 | June 27, 2017 | |
| NCT03679767 | Completed | Phase 2 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | January 9, 2019 | June 28, 2022 |
| NCT01621490 | Completed | Phase 1 | PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma | September 27, 2012 | October 25, 2018 |
| NCT03625141 | Completed | Phase 2 | A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | December 13, 2018 | April 13, 2023 |
| NCT03590054 | Completed | Phase 1 | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | August 20, 2018 | November 30, 2023 |
| NCT01738139 | Completed | Phase 1 | Ipilimumab and Imatinib Mesylate in Advanced Cancer | February 19, 2013 | December 13, 2023 |
| NCT01740557 | Completed | Phase 1/Phase 2 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | January 28, 2015 | April 21, 2023 |
| NCT01743157 | Completed | Phase 1/Phase 2 | Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma | December 2010 | May 2013 |
| NCT01807182 | Completed | Phase 2 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | August 20, 2013 | August 26, 2021 |
| NCT03415126 | Completed | Phase 1 | A Study of ASN007 in Patients With Advanced Solid Tumors | January 19, 2018 | June 30, 2020 |
| NCT03326973 | Completed | Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors | October 25, 2017 | December 14, 2020 | |
| NCT03229278 | Completed | Phase 1 | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | October 3, 2017 | October 30, 2022 |
| NCT01876212 | Completed | Phase 2 | Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma | May 16, 2014 | July 31, 2019 |
| NCT03225365 | Completed | N/A | Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma | October 10, 2019 | June 15, 2021 |
| NCT03176485 | Completed | N/A | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | October 17, 2014 | November 1, 2018 |
| NCT01904123 | Completed | Phase 1 | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain | July 13, 2018 | March 16, 2022 |
| NCT01927419 | Completed | Phase 2 | Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma | August 23, 2013 | February 26, 2021 |
| NCT01932489 | Completed | N/A | The Jules Bordet Institute Molecular Profiling Program Feasibility Trial | December 2013 | October 2014 |
| NCT03155217 | Completed | Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old | May 5, 2017 | December 31, 2018 | |
| NCT01993719 | Completed | Phase 2 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | December 12, 2013 | July 6, 2022 |
| NCT03123783 | Completed | Phase 1/Phase 2 | CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab | July 10, 2017 | November 16, 2020 |
| NCT02009397 | Completed | Phase 1/Phase 2 | A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | February 2012 | November 2016 |
| NCT02027935 | Completed | Phase 2 | CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma | January 22, 2015 | April 12, 2024 |
| NCT02038348 | Completed | Phase 2 | Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study | February 16, 2016 | October 28, 2022 |
| NCT02073123 | Completed | Phase 1/Phase 2 | Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | July 2014 | July 3, 2019 |
| NCT02862743 | Completed | N/A | Molecular Characterization of Advanced Stage Melanoma by Blood Sampling | January 14, 2016 | December 31, 2019 |
| NCT02117362 | Completed | Phase 1 | Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma | May 8, 2014 | November 28, 2018 |
| NCT02126579 | Completed | Phase 1/Phase 2 | Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists | May 1, 2014 | May 5, 2021 |
| NCT02141542 | Completed | Phase 1 | Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma | May 2014 | September 23, 2020 |
| NCT02858869 | Completed | Phase 1 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | October 4, 2016 | October 28, 2023 |
| NCT02150369 | Completed | Interleukin-2-Induced Cognitive/Affective/Sleep Symptoms | February 16, 2015 | March 2, 2017 | |
| NCT02158520 | Completed | Phase 2 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | October 18, 2013 | October 30, 2019 |
| NCT02177110 | Completed | A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma | September 2014 | ||
| NCT02644967 | Completed | Phase 2 | A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma | December 2015 | May 2021 |
| NCT00121680 | Completed | Phase 1 | A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma | July 2005 | May 2015 |
| NCT00139360 | Completed | Phase 2 | Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma | May 2005 | July 2011 |
| NCT00203879 | Completed | Phase 2 | Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma | February 2002 | May 2007 |
| NCT00223899 | Completed | Phase 1 | A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma | July 2005 | October 2008 |
| NCT06369428 | Completed | Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Metastatic Melanoma Patients | June 23, 2021 | April 13, 2023 | |
| NCT00244816 | Completed | Phase 2 | Taxoprexin® Treatment for Advanced Eye Melanoma | October 2005 | April 2007 |
| NCT00249262 | Completed | Phase 2 | Taxoprexin Treatment for Advanced Skin Melanoma | October 2005 | April 2007 |
| NCT00256282 | Completed | Phase 2 | Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | April 2003 | August 2012 |
| NCT00279058 | Completed | Phase 1/Phase 2 | The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 | December 2005 | December 2008 |
| NCT00301067 | Completed | Phase 1/Phase 2 | Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma | January 30, 2005 | July 9, 2012 |
| NCT00304460 | Completed | Phase 1 | Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer | March 13, 2006 | February 27, 2014 |
| NCT00304525 | Completed | Phase 1/Phase 2 | A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma | April 2006 | November 2013 |
| NCT00308607 | Completed | Phase 2 | Bevacizumab, Dacarbazine and Interferon-Alfa to Treat Metastatic Melanoma | August 2005 | April 2009 |
| NCT00314093 | Completed | Phase 2 | RFT-5-dgA in Patients With Metastatic Melanoma | April 2006 | November 2008 |
| NCT00314106 | Completed | Phase 2 | Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | April 2006 | March 2009 |
| NCT00328861 | Completed | Phase 2 | Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | May 2006 | April 2009 |
| NCT00348088 | Completed | Melanoma Biomarker Study | May 2006 | September 2011 | |
| NCT00383292 | Completed | Phase 2 | A Study of Tasisulam in Treating Participants With Malignant Melanoma | November 2006 | July 2015 |
| NCT00395070 | Completed | Phase 3 | A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma | October 2006 | July 2013 |
| NCT00399113 | Completed | Phase 1 | Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | May 2007 | |
| NCT05954546 | Completed | A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings | July 21, 2023 | December 31, 2023 | |
| NCT00414765 | Completed | Phase 4 | Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma | September 3, 2008 | March 28, 2010 |
| NCT00520299 | Completed | Phase 1/Phase 2 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | July 2007 | March 2010 |
| NCT00526617 | Completed | Phase 1 | A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients | August 2007 | |
| NCT00527761 | Completed | Phase 1 | Taxotere/Temodar/Cisplatin Study in Melanoma Patients | August 2004 | November 2007 |
| NCT05810740 | Completed | Phase 1 | Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations | August 31, 2022 | January 18, 2023 |
| NCT00591734 | Completed | Phase 2 | RAD001 Plus Bevacizumab in Metastatic Melanoma | January 2008 | October 2011 |
| NCT00597038 | Completed | Phase 1/Phase 2 | A Phase I/II Study of Dasatinib and Dacarbazine | November 2007 | September 2011 |
| NCT00609011 | Completed | Phase 1/Phase 2 | Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma | March 2008 | August 2009 |
| NCT00626860 | Completed | Phase 1/Phase 2 | The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma | July 2000 | September 10, 2008 |
| NCT00631618 | Completed | Phase 2 | Clinical Trial of Sutent to Treat Metastatic Melanoma | September 2007 | March 2012 |
| NCT00665470 | Completed | Phase 2 | Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma | April 2008 | April 2012 |
| NCT00668512 | Completed | Phase 1 | Intratumoral Injection Of Alpha-Gal Glycosphingolipids | March 2007 | March 2014 |
| NCT00672542 | Completed | Phase 1 | Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells | January 2008 | July 2013 |
| NCT00679289 | Completed | Phase 2 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | March 28, 2008 | February 3, 2014 |
| NCT05611229 | Completed | Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | June 16, 2020 | December 3, 2021 | |
| NCT00730639 | Completed | Phase 1 | A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies | October 30, 2008 | December 22, 2020 |
| NCT00734188 | Completed | Phase 1 | Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma | January 2009 | June 2010 |
| NCT00804908 | Completed | Phase 2 | A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma | February 2009 | January 2016 |
| NCT00881049 | Completed | Phase 2 | Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma | December 2008 | January 2011 |
| NCT00910650 | Completed | Phase 2 | Study of Gene Modified Immune Cells in Patients With Advanced Melanoma | October 13, 2009 | May 30, 2019 |
| NCT00928031 | Completed | Long-term Data Collection for Subjects in MDX-010 Studies | June 2007 | April 2009 | |
| NCT00948480 | Completed | Phase 2 | Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells | October 2000 | September 2007 |
| NCT00984464 | Completed | Phase 2 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | September 2009 | October 2014 |
| NCT01005472 | Completed | Phase 1 | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma | December 1, 2008 | January 17, 2018 |
| NCT01011530 | Completed | Phase 1 | Dose Escalation Study of MLN4924 in Adults With Melanoma | December 2009 | January 2013 |
| NCT01014351 | Completed | Phase 2 | Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | February 2010 | August 2013 |
| NCT01029873 | Completed | Phase 1/Phase 2 | QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma | February 2010 | September 2013 |
| NCT00044356 | Completed | Phase 2 | Phase II Trial of Allovectin-7® for Metastatic Melanoma | February 2001 | September 2004 |
| NCT01118091 | Completed | Phase 2 | Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... | April 2010 | April 2012 |
| NCT02791594 | Completed | Imaging FDG Flare in Melanoma | June 2016 | July 1, 2020 | |
| NCT02424916 | Completed | Phase 1/Phase 2 | Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study | May 26, 2015 | May 6, 2019 |
| NCT02768207 | Completed | Phase 2 | A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | May 23, 2016 | June 27, 2019 |
| NCT02500576 | Completed | Phase 2 | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | August 7, 2015 | October 12, 2022 |
| NCT02755233 | Completed | Ipilimumab-induced Lung Toxicity: Observational Study | January 2014 | March 2016 | |
| NCT02713269 | Completed | Phase 2 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | August 29, 2016 | September 26, 2023 |
| NCT02700971 | Completed | N/A | RATIO: Rational Approach To Immuno-Oncology | June 23, 2016 | September 8, 2023 |
| NCT02678741 | Completed | Phase 1/Phase 2 | Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease. | February 2016 | November 13, 2019 |
| NCT02631447 | Completed | Phase 2 | Sequential Combo Immuno and Target Therapy (SECOMBIT) Study | November 14, 2016 | May 31, 2024 |
| NCT02304458 | Completed | Phase 1/Phase 2 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | March 30, 2015 | March 31, 2023 |
| NCT02306850 | Completed | Phase 2 | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | January 2015 | June 8, 2018 |
| NCT02310451 | Completed | N/A | Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes | December 2014 | July 31, 2023 |
| NCT02354690 | Completed | Phase 1/Phase 2 | Vemurafenib and TIL Therapy for Metastatic Melanoma | November 2014 | December 31, 2018 |
| NCT02857270 | Completed | Phase 1 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | September 29, 2016 | October 24, 2022 |
| NCT02379195 | Completed | Phase 1/Phase 2 | Peginterferon and TIL Therapy for Metastatic Melanoma | November 2014 | October 2018 |
| NCT02392871 | Completed | Phase 1/Phase 2 | Radiotherapy & Combi in Metastatic Melanoma | May 2015 | April 17, 2020 |
| NCT05398640 | No longer available | Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | |||
| NCT04129515 | Not yet recruiting | Phase 1/Phase 2 | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | April 15, 2024 | January 2027 |
| NCT05304546 | Not yet recruiting | Phase 2 | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | June 2023 | June 2027 |
| NCT05629546 | Not yet recruiting | Phase 1 | Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors | June 30, 2024 | June 30, 2030 |
| NCT03803397 | Not yet recruiting | Phase 1 | Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma | April 1, 2024 | December 31, 2024 |
| NCT05717140 | Not yet recruiting | Phase 1 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | June 2024 | April 2025 |
| NCT06066138 | Not yet recruiting | Phase 1 | A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | June 23, 2024 | November 29, 2026 |
| NCT05641012 | Not yet recruiting | Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma | December 1, 2022 | May 1, 2025 | |
| NCT06424626 | Not yet recruiting | Phase 1 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | May 21, 2024 | December 31, 2027 |
| NCT05269381 | Recruiting | Phase 1/Phase 2 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | March 31, 2022 | February 24, 2026 |
| NCT03047928 | Recruiting | Phase 1/Phase 2 | Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma | February 22, 2018 | April 1, 2023 |
| NCT03474497 | Recruiting | Phase 1/Phase 2 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | May 20, 2019 | December 2023 |
| NCT03645928 | Recruiting | Phase 2 | Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | May 7, 2019 | August 9, 2029 |
| NCT03646617 | Recruiting | Phase 2 | Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma | November 27, 2018 | December 31, 2025 |
| NCT03743298 | Recruiting | Phase 1 | Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma | April 21, 2021 | May 2026 |
| NCT03888950 | Recruiting | N/A | Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy | November 24, 2020 | November 2027 |
| NCT03991741 | Recruiting | Phase 1 | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors | October 7, 2020 | August 2026 |
| NCT04007744 | Recruiting | Phase 1 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | February 13, 2020 | July 2024 |
| NCT04109456 | Recruiting | Phase 1 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | March 16, 2020 | September 30, 2024 |
| NCT04119024 | Recruiting | Phase 1 | Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | November 27, 2019 | October 1, 2025 |
| NCT04140500 | Recruiting | Phase 1/Phase 2 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | November 11, 2019 | December 31, 2025 |
| NCT04140526 | Recruiting | Phase 1/Phase 2 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | September 16, 2020 | December 31, 2027 |
| NCT04272658 | Recruiting | PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy | June 26, 2020 | June 26, 2026 | |
| NCT04478279 | Recruiting | Phase 1/Phase 2 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | July 1, 2020 | December 2025 |
| NCT04511013 | Recruiting | Phase 2 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | January 6, 2021 | June 30, 2027 |
| NCT04557956 | Recruiting | Phase 1/Phase 2 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | August 19, 2021 | December 4, 2024 |
| NCT04588246 | Recruiting | Phase 3 | Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | December 15, 2020 | January 31, 2030 |
| NCT04616248 | Recruiting | Phase 1 | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | January 9, 2023 | January 9, 2026 |
| NCT04625205 | Recruiting | Phase 1 | NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma | December 1, 2020 | October 31, 2025 |
| NCT04633902 | Recruiting | Phase 2 | Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation | March 3, 2021 | December 31, 2024 |
| NCT04645680 | Recruiting | Phase 2 | Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study | June 24, 2020 | February 1, 2026 |
| NCT04693377 | Recruiting | N/A | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | March 16, 2021 | April 1, 2027 |
| NCT04697576 | Recruiting | Phase 1 | Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | October 20, 2021 | December 31, 2025 |
| NCT04771520 | Recruiting | Phase 2 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | January 20, 2021 | February 3, 2025 |
| NCT04793737 | Recruiting | N/A | Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases | March 8, 2021 | December 2025 |
| NCT04903119 | Recruiting | Phase 1 | Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | June 1, 2022 | March 31, 2027 |
| NCT04911998 | Recruiting | A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients | February 2, 2021 | December 2024 | |
| NCT04930783 | Recruiting | Phase 1 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | January 3, 2022 | January 31, 2027 |
| NCT04941430 | Recruiting | N/A | 7T MRI Scan for the Early Detection of Melanoma Brain Metastases | June 25, 2021 | December 31, 2025 |
| NCT04955743 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | February 9, 2022 | March 31, 2028 |
| NCT04960059 | Recruiting | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | February 14, 2022 | December 1, 2024 | |
| NCT05026983 | Recruiting | Phase 2 | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | December 27, 2021 | May 1, 2025 |
| NCT05034536 | Recruiting | Phase 2 | PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma | February 7, 2022 | June 30, 2026 |
| NCT05155033 | Recruiting | Phase 2 | Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | August 18, 2022 | September 1, 2027 |
| NCT05341349 | Recruiting | Phase 1 | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases | October 13, 2022 | March 6, 2025 |
| NCT05361174 | Recruiting | Phase 1/Phase 2 | A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | July 20, 2022 | June 2027 |
| NCT05388877 | Recruiting | Phase 1 | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma | September 30, 2022 | December 2025 |
| NCT05578872 | Recruiting | Phase 1/Phase 2 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | December 16, 2022 | December 2024 |
| NCT05588453 | Recruiting | Phase 1/Phase 2 | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain | January 1, 2023 | December 31, 2025 |
| NCT05607095 | Recruiting | Phase 1 | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma | November 1, 2022 | May 1, 2025 |
| NCT05628883 | Recruiting | Phase 1 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | November 22, 2022 | December 31, 2026 |
| NCT05655312 | Recruiting | Phase 1/Phase 2 | MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma | June 1, 2023 | June 30, 2027 |
| NCT05727904 | Recruiting | Phase 3 | Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | March 30, 2023 | March 1, 2030 |
| NCT05750511 | Recruiting | Multicenter Tissue Registry in Melanoma | February 1, 2014 | February 1, 2025 | |
| NCT05764395 | Recruiting | Phase 2 | Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | May 9, 2023 | May 1, 2029 |
| NCT05779423 | Recruiting | Phase 2 | Cryoablation+Ipilimumab+Nivolumab in Melanoma | September 23, 2023 | January 1, 2028 |
| NCT05786924 | Recruiting | Phase 1 | A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers | April 18, 2023 | December 2026 |
| NCT05848739 | Recruiting | Phase 1 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | June 5, 2023 | May 31, 2027 |
| NCT05856565 | Recruiting | Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1 | July 24, 2023 | July 24, 2028 | |
| NCT05878977 | Recruiting | N/A | Biomarkers in Immunotherapy of Melanoma | October 5, 2022 | December 31, 2027 |
| NCT05896839 | Recruiting | Phase 1/Phase 2 | Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | August 11, 2024 | January 31, 2027 |
| NCT05913388 | Recruiting | Phase 2 | GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma | February 29, 2024 | February 2030 |
| NCT06060613 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of OBX-115 in Advanced Solid Tumors | October 25, 2023 | October 30, 2027 |
| NCT06075524 | Recruiting | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types | June 15, 2015 | December 31, 2025 | |
| NCT06151847 | Recruiting | Phase 2 | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | December 21, 2023 | November 27, 2025 |
| NCT06180460 | Recruiting | N/A | CALM: Managing Distress in Malignant Brain Cancer | November 10, 2023 | July 31, 2025 |
| NCT06236360 | Recruiting | N/A | Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet | December 21, 2023 | December 1, 2025 |
| NCT01457131 | Terminated | Phase 1 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | October 6, 2011 | August 7, 2013 |
| NCT01218867 | Terminated | Phase 1/Phase 2 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | November 10, 2010 | December 15, 2015 |
| NCT01216436 | Terminated | Phase 1 | Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma | January 2010 | October 2013 |
| NCT01212276 | Terminated | Phase 1 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | December 2010 | September 2012 |
| NCT01191034 | Terminated | Phase 1/Phase 2 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | August 2010 | August 1, 2012 |
| NCT04899921 | Terminated | Phase 2 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | June 30, 2021 | May 29, 2023 |
| NCT00402662 | Terminated | Phase 2 | A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma | February 2006 | June 2006 |
| NCT02740920 | Terminated | Phase 2 | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | January 10, 2017 | September 30, 2019 |
| NCT02748564 | Terminated | Phase 2 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | March 21, 2017 | June 5, 2023 |
| NCT02521870 | Terminated | Phase 1/Phase 2 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | September 2015 | April 2020 |
| NCT02414750 | Terminated | Phase 2 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma | December 2014 | November 2020 |
| NCT02375984 | Terminated | Phase 2 | A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas | March 16, 2016 | June 1, 2017 |
| NCT02097732 | Terminated | Phase 2 | Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery | April 2014 | July 2020 |
| NCT02062359 | Terminated | Phase 2 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma | February 2014 | February 2016 |
| NCT00724841 | Terminated | Phase 1/Phase 2 | A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma | June 2008 | August 2010 |
| NCT03073473 | Terminated | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers | February 28, 2017 | June 13, 2018 | |
| NCT02054520 | Terminated | Phase 2 | Immunotherapy Study for Patients With Stage IV Melanoma | June 2014 | January 5, 2021 |
| NCT02009384 | Terminated | Phase 2 | Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox | January 2012 | October 2014 |
| NCT01995344 | Terminated | Phase 2 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment | March 1, 2014 | July 24, 2015 |
| NCT01940809 | Terminated | Phase 1 | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | August 28, 2013 | March 4, 2022 |
| NCT01876641 | Terminated | Phase 1 | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | October 2013 | September 2018 |
| NCT01864538 | Terminated | Phase 2 | A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma | May 2013 | September 2015 |
| NCT03265080 | Terminated | Phase 1 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens | March 28, 2018 | November 12, 2020 |
| NCT01856023 | Terminated | Phase 4 | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma | May 2013 | July 2015 |
| NCT01838200 | Terminated | Phase 1 | Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma | March 2014 | August 17, 2015 |
| NCT03425461 | Terminated | Phase 1 | Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma | June 14, 2018 | March 4, 2021 |
| NCT01723813 | Terminated | Phase 1/Phase 2 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | April 2012 | April 1, 2015 |
| NCT03445533 | Terminated | Phase 3 | A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | May 30, 2018 | June 1, 2021 |
| NCT01160445 | Terminated | Phase 2 | Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer | June 2010 | January 2012 |
| NCT01689974 | Terminated | Phase 2 | Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma | January 2013 | March 2015 |
| NCT03526185 | Terminated | Early Phase 1 | A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes | February 6, 2018 | December 1, 2020 |
| NCT03597282 | Terminated | Phase 1 | A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | October 8, 2018 | August 11, 2020 |
| NCT01683188 | Terminated | Phase 4 | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma | August 2012 | November 2014 |
| NCT03674502 | Terminated | Phase 1 | Safety of ADU-1604 in Adults With Metastatic Melanoma | November 8, 2018 | August 9, 2019 |
| NCT03698162 | Terminated | N/A | Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases | April 13, 2021 | November 22, 2023 |
| NCT01542255 | Terminated | Phase 2 | Metronomic Therapy in Patients With Metastatic Melanoma | June 2010 | January 2013 |
| NCT03724968 | Terminated | Phase 2 | Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression | January 17, 2019 | May 28, 2020 |
| NCT03728465 | Terminated | Phase 2 | Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma | April 10, 2018 | January 1, 2021 |
| NCT01495988 | Terminated | Phase 2 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | August 2013 | June 2016 |
| NCT01495572 | Terminated | Phase 2 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | December 2011 | February 2014 |
| NCT01468818 | Terminated | Phase 2 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | September 2011 | August 2013 |
| NCT01369888 | Terminated | Phase 1/Phase 2 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | May 2011 | May 2014 |
| NCT01369875 | Terminated | Phase 2 | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | June 17, 2011 | February 14, 2012 |
| NCT00716560 | Terminated | Nausea and Vomiting In Patients Receiving Consecutive Days of Cisplatin | May 2005 | March 2009 | |
| NCT00670748 | Terminated | Phase 2 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | May 29, 2008 | June 29, 2016 |
| NCT01082887 | Terminated | Phase 1/Phase 2 | A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg) | January 2010 | October 2012 |
| NCT00627419 | Terminated | Phase 2 | A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma | February 2008 | October 2009 |
| NCT00571116 | Terminated | Phase 1 | Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy | September 2006 | August 2012 |
| NCT01280565 | Terminated | Phase 3 | Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit | January 2011 | August 2019 |
| NCT00612222 | Terminated | Phase 2 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | January 2008 | March 2011 |
| NCT04337931 | Terminated | Phase 2 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | June 12, 2019 | August 2, 2022 |
| NCT01055522 | Terminated | Phase 2 | Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma | June 2008 | February 2014 |
| NCT01042366 | Terminated | Phase 2 | Dendritic Cells (DC) Vaccine for Metastatic Melanoma | October 2002 | November 2014 |
| NCT01273181 | Terminated | Phase 1/Phase 2 | MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes | December 2010 | December 2012 |
| NCT01032122 | Terminated | Phase 1 | Rituximab in Metastatic Melanoma | October 2007 | May 2011 |
| NCT00925132 | Terminated | Phase 1/Phase 2 | Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat | December 2009 | December 2016 |
| NCT00610311 | Terminated | Phase 2 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | January 2008 | February 2011 |
| NCT05848219 | Terminated | Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib | October 16, 2021 | April 27, 2022 | |
| NCT00758797 | Terminated | Phase 1 | A Novel Treatment for Metastatic Melanoma | April 2008 | October 2012 |
| NCT00747825 | Terminated | Phase 1 | Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma | December 2009 | September 2011 |
| NCT01236573 | Terminated | Phase 1/Phase 2 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | October 2010 | March 2015 |
| NCT00733798 | Terminated | Phase 1/Phase 2 | A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma | ||
| NCT00226473 | Unknown status | Phase 4 | Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma | September 2001 | September 2005 |
| NCT01503827 | Unknown status | N/A | Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma | October 2007 | June 2022 |
| NCT00287131 | Unknown status | Phase 2 | Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients | January 2006 | November 2013 |
| NCT03925350 | Unknown status | Phase 2 | Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation | March 20, 2019 | February 2023 |
| NCT02142335 | Unknown status | Phase 2 | Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma | March 2014 | March 2016 |
| NCT02625337 | Unknown status | Phase 2 | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients | January 2016 | December 2018 |
| NCT00604136 | Unknown status | Phase 2 | Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | July 2008 | July 2020 |
| NCT02097225 | Unknown status | Phase 1 | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | May 29, 2014 | |
| NCT03013101 | Unknown status | Phase 2 | Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | December 28, 2016 | December 2021 |
| NCT00153569 | Unknown status | Phase 2 | Multiepitope Peptide Vaccination in Melanoma | March 2003 | September 2005 |
| NCT01620749 | Unknown status | Early Phase 1 | Of 18F MEL050 Using PET/CT in Metastatic Melanoma | June 2010 | December 2012 |
| NCT02608437 | Unknown status | Phase 1 | A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients | October 2015 | October 2018 |
| NCT05103891 | Unknown status | Phase 1 | Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations | September 3, 2021 | November 29, 2021 |
| NCT04158544 | Unknown status | Immune Monitoring in Metastatic Melanoma | August 1, 2016 | July 31, 2021 | |
| NCT02626065 | Unknown status | Phase 4 | Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies | April 23, 2015 | April 2018 |
| NCT04021420 | Unknown status | Phase 1/Phase 2 | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma | October 24, 2019 | July 5, 2023 |
| NCT01920516 | Unknown status | Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment | July 2013 | July 2020 | |
| NCT05510466 | Unknown status | Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis | January 1, 2019 | March 1, 2023 | |
| NCT01878396 | Unknown status | Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors | December 2011 | December 2017 | |
| NCT04759846 | Withdrawn | Phase 1 | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | January 21, 2021 | May 2023 |
| NCT01416844 | Withdrawn | Phase 2 | Study of Immune Responses in Patients With Metastatic Melanoma | September 2012 | September 2012 |
| NCT03126461 | Withdrawn | Phase 2 | SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients | March 1, 2018 | December 31, 2022 |
| NCT04955262 | Withdrawn | Phase 1 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab | August 2019 | January 2022 |
| NCT01340729 | Withdrawn | Phase 1/Phase 2 | Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | September 2013 | |
| NCT04042506 | Withdrawn | Phase 2 | SBRT as a Vaccination for Metastatic Melanoma | November 26, 2019 | January 26, 2021 |
| NCT04060407 | Withdrawn | Phase 1/Phase 2 | CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | June 15, 2021 | December 30, 2023 |
| NCT04987996 | Withdrawn | Phase 2 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | July 1, 2023 | July 1, 2031 |
| NCT01312506 | Withdrawn | Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls | July 2012 | November 2012 | |
| NCT01933061 | Withdrawn | Phase 2 | Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma | January 2014 | January 2014 |
| NCT04242329 | Withdrawn | Phase 2 | Surgery of Melanoma Metastases After Systemic Therapy | March 11, 2021 | September 13, 2023 |
| NCT02489266 | Withdrawn | Phase 1 | In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma | June 24, 2015 | June 29, 2016 |
| NCT04941365 | Withdrawn | N/A | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy | July 7, 2022 | March 2024 |
| NCT02357732 | Withdrawn | Phase 1 | Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | August 2015 | August 2015 |
| NCT03773744 | Withdrawn | Phase 1 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma | February 15, 2020 | December 31, 2021 |
| NCT02065466 | Withdrawn | Phase 1/Phase 2 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | July 2014 | August 2015 |
| NCT03297463 | Withdrawn | Phase 1/Phase 2 | Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma | January 31, 2018 | February 1, 2020 |
| NCT03326258 | Withdrawn | Phase 1/Phase 2 | Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery | April 20, 2018 | April 20, 2018 |
| NCT01689870 | Withdrawn | Phase 1/Phase 2 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | March 2014 | August 2014 |
| NCT04703426 | Withdrawn | Phase 2 | Sargramostim (GM-CSF) + PD-1 | April 16, 2021 | June 9, 2025 |
| NCT01833767 | Withdrawn | Phase 2 | Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma | October 2012 | December 2015 |